Literature DB >> 22435503

Inflammatory bowel disease in the 21(st) century in China: turning challenges into opportunities.

Qin Ouyang1, Lin Yun Xue.   

Abstract

Inflammatory bowel disease (IBD) has been an international hot spot for research for a long period of time. In China, the prevalence of IBD is rapidly increasing in recent years, mimicking the same fast growing footsteps of the developed world. Chinese literature of the 20(th) century shows that the total number of IBD cases increased by approximately 2.5-fold over the previous decade, in particular a 15.7-fold in patients with Crohn's disease (CD). Articles on basic research have increased 4.3-fold, with a particular 9.9-fold increase on immunological mechanisms. The predominantly Traditional Chinese Medicine (TCM) related clinical trials implied tendency to use a combination of Western Medicine and TCM in the management of Chinese IBD patients. IBD research and collaborations overseas have been markedly promoted since the Chinese Organization for the Study of Inflammatory Bowel Disease (COIBD) was founded at the beginning of the 21(st) century. From the second decade of the century onwards, we need to focus on the research hot spots to catch up with the rapid advances worldwide. Big challenges and present achievements provide us with great opportunities for further developments of the study on IBD. The development of some novel target pathogenic factors of the disease will provide us with more effective roll for modern management and optimistic treatment of IBD during this century.
© 2012 The Authors. Journal of Digestive Diseases © 2012 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22435503     DOI: 10.1111/j.1751-2980.2012.00579.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  8 in total

Review 1.  Role of high-mobility group box 1 protein in inflammatory bowel disease.

Authors:  Zhen Hu; Xiaoyun Wang; Lei Gong; Gaojue Wu; Xiaobin Peng; Xuejun Tang
Journal:  Inflamm Res       Date:  2015-06-16       Impact factor: 4.575

Review 2.  Where are we on worms?

Authors:  David E Elliott; Joel V Weinstock
Journal:  Curr Opin Gastroenterol       Date:  2012-11       Impact factor: 3.287

3.  Chinese research into severe ulcerative colitis has increased in quantity and complexity.

Authors:  Cheng-Xin Luo; Zhong-Hui Wen; Yu Zhen; Zhu-Jun Wang; Jing-Xi Mu; Min Zhu; Qin Ouyang; Hu Zhang
Journal:  World J Clin Cases       Date:  2018-03-16       Impact factor: 1.337

4.  A Systematic Review of Epidemiology and Risk Factors Associated With Chinese Inflammatory Bowel Disease.

Authors:  Guanglin Cui; Aping Yuan
Journal:  Front Med (Lausanne)       Date:  2018-06-19

5.  Efficacy and safety of heat-sensitive moxibustion in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis.

Authors:  Jinlong Wang; Quanhui Zhang; Yongwen Deng; Gen Deng; Feihong Huang; Yiduo Zhou; Mingyan Jia; Haoran Yi
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

6.  Fluorescent quantitative PCR of Mycobacterium tuberculosis for differentiating intestinal tuberculosis from Crohn's disease.

Authors:  B Y Fei; H X Lv; W H Zheng
Journal:  Braz J Med Biol Res       Date:  2014-01-24       Impact factor: 2.590

7.  Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis.

Authors:  Shan-Shan Gong; Yi-Hong Fan; Shi-Yi Wang; Qing-Qing Han; Bin Lv; Yi Xu; Xi Chen; Yao-Er He
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

8.  Development of a Traditional Chinese Medicine Syndrome-Specific Scale for Ulcerative Colitis: The Large Intestine Dampness-Heat Syndrome Questionnaire.

Authors:  Xin-Lin Chen; Yi Wen; Zu-Chun Wu; Bei-Ping Zhang; Zheng-Kun Hou; Jun-Lin Xiao; Man-Qing Lin; Yue Hu; Zhe-Li Wu; Jie-Min Deng; Feng-Bin Liu; Tian-Wen Liu
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-12       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.